

AMENDMENTS TO CLAIMS (Marked up copy)**WHAT IS CLAIMED IS:**

1. (Currently amended) An isolated, ~~or purified~~ peptide, consisting essentially of the a tripeptide of amino acid sequence L- Tyrosyl-L-Seryl-L-Valine.
2. (Canceled)
3. (Currently amended) A pharmaceutical composition, comprising a purified, isolated tripeptide of amino acid sequence polypeptide consisting of the tripeptide L-Tyrosyl-L-Seryl-L-Valine.
4. (Currently amended) A method of ~~reducing the condition of a human disease comprising administering a pharmaceutically effective dose of the tripeptide Tyrosyl-Seryl-Valine to a human, wherein said human disease is selected from the group consisting of a condition whose effects can be reduced by stimulating T lymphocyte transformation and a cell proliferative disorder, , countering or inhibiting T-lymphocyte transformation or cell proliferation, or a disease or condition associated with it, comprising administering to a subject in need of treatment a therapeutically effective amount of a tripeptide of amino acid sequence Tyrosyl-Seryl-Valine.~~
5. (Currently amended) The method of Claim 4, wherein said cell proliferative disorder is cancer, wherein the disease or condition is associated with, or comprises a cancer.
6. (Currently amended) The method of Claim 5, 4~~wherein said cancer is selected from the group consisting of liver cancer, leukemia, lung cancer, melanoma and cervical cancer, wherein the disease or condition is associated with, or comprises liver cancer, leukemia, lung cancer, melanoma or cervical cancer.~~
7. (Canceled)
8. (Canceled)
9. (New) The peptide of claim 1, which comprises a substantially pure tripeptide.
10. (New) The method of claim 4, wherein the therapeutically effective amount of the tripeptide comprises an anti-T-cell transformation, anti-cell proliferation, or anti-cancer effective amount of the tripeptide.
11. (New) The method of claim 4, wherein the therapeutically effective amount of the tripeptide comprises a liver cancer, leukemia cell, cervical cancer, lung cancer or melanoma growth countering, reducing or inhibiting amount of the tripeptide.
12. (New) The method of claim 4, wherein the tripeptide is administered as a pharmaceutical composition further comprising a pharmaceutically or biologically acceptable carrier.